<code id='4361C6AA38'></code><style id='4361C6AA38'></style>
    • <acronym id='4361C6AA38'></acronym>
      <center id='4361C6AA38'><center id='4361C6AA38'><tfoot id='4361C6AA38'></tfoot></center><abbr id='4361C6AA38'><dir id='4361C6AA38'><tfoot id='4361C6AA38'></tfoot><noframes id='4361C6AA38'>

    • <optgroup id='4361C6AA38'><strike id='4361C6AA38'><sup id='4361C6AA38'></sup></strike><code id='4361C6AA38'></code></optgroup>
        1. <b id='4361C6AA38'><label id='4361C6AA38'><select id='4361C6AA38'><dt id='4361C6AA38'><span id='4361C6AA38'></span></dt></select></label></b><u id='4361C6AA38'></u>
          <i id='4361C6AA38'><strike id='4361C6AA38'><tt id='4361C6AA38'><pre id='4361C6AA38'></pre></tt></strike></i>

          hotspot

          hotspot

          author:fashion    Page View:158
          Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC.
          Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

          NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

          Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

          advertisement

          Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          Positive childhood experiences can help future health
          Positive childhood experiences can help future health

          MikeReddyforSTATIwasrecentlyworkingwithayoungmotherwhostruggledwithdepressionandanxietyinthedifficul

          read more
          Walensky prepares to leave CDC — and Congress — behind
          Walensky prepares to leave CDC — and Congress — behind

          OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

          read more

          I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

          MollyFerguson/STATIwaswrongaboutGeron.Foryears,I’vebelieved—anddeclaredpublicly—thatGeron’sefforttod